- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02452515
A Single-blind Pilot Study to Investigate Safety and Tolerability of the Chymase Inhibitor BAY1142524 in Clinically Stable Patients With Left-ventricular Dysfunction (CHIARA MIA 1)
A Single-blind, Multicenter Pilot Study to Investigate the Safety and Tolerability of a 14 Day Oral Treatment With Different Doses of the Chymase Inhibitor BAY1142524 in Comparison to Placebo in Clinically Stable Patients With Left-ventricular Dysfunction After Myocardial Infarction
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Copenhagen, Denmark, DK-2400
-
Copenhagen Ø, Denmark, 2100
-
Hellerup, Denmark, 2900
-
Herlev, Denmark, 2730
-
-
-
-
-
Berlin, Germany, 13353
-
-
Hessen
-
Frankfurt, Hessen, Germany, 60594
-
-
Nordrhein-Westfalen
-
Düsseldorf, Nordrhein-Westfalen, Germany, 40225
-
-
Thüringen
-
Erfurt, Thüringen, Germany, 99084
-
-
-
-
Lombardia
-
Bergamo, Lombardia, Italy, 24127
-
Brescia, Lombardia, Italy, 25123
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Clinically stable patients with left-ventricular dysfunction (LVEF ≤ 45%) after myocardial infarction, whereby the MI occurred 6 or more months before randomization.
- New York Heart Association (NYHA) class I-II.
- Left-ventricular ejection fraction ≤ 45%, confirmed by any imaging technique within the last 3 months prior to screening visit will be accepted for screening purposes. If no data are available, an echocardiography has to be performed at screening for inclusion.
- Treatment with evidence-based therapy for left-ventricular dysfunction post MI for at least 4 weeks prior to screening visit. This therapy has to include at least an Angiotensin-converting enzyme (ACE) inhibitor or an Angiotensin receptor blockers (ARB). Beta-blockers, diuretics, mineralocorticoid receptor antagonist (MRAs), antiplatelet therapy, statins, and aspirin are to be used if indicated. Treatment with stable doses of ACE inhibitors or ARBs using at least half of the recommended target dose (as defined in the European Society of Cardiology (ESC) guidelines, see appendix 16.4) ≥ 4 weeks prior to the screening visit is mandatory.
- No planned changes to post MI drug therapy during the active treatment phase of the study.
- Men or confirmed postmenopausal women (defined as being amenorrheic for longer than 2 years with an appropriate clinical profile, e.g. age appropriate and a history of vasomotor symptoms) or women without childbearing potential based on surgical treatment such as bilateral tubal ligation, bilateral oophorectomy or hysterectomy (documented by medical report verification).
Men of reproductive potential must agree to use 2 reliable and acceptable methods for contraception simultaneously when sexually active and not to act as sperm donor. This applies for the time period between signing of the informed consent form and 12 weeks after the last administration of study drug.
Acceptable methods of contraception include, but are not limited to, (i) condoms (male or female) with or without a spermicidal agent; (ii) diaphragm or cervical cap with spermicide; (iii) intra-uterine device; (iv) hormone-based contraception.
- Age: 40 to 79 years (inclusive) at the screening visit.
- Race: Caucasian
Exclusion Criteria:
- Non-ischemic causes for cardiomyopathy will be excluded (including, but not limited to: primary cardiomyopathy, constrictive, restrictive or hypertrophic cardiomyopathy, acute myocarditis, cardiomyopathy secondary to cardiotoxic chemotherapeutic agents).
- Hospitalization for decompensated heart failure within the last 3 months prior to randomization.
- Coronary revascularization within 6 weeks prior to randomization or if revascularization is anticipated or needed during the study duration.
- Clinically relevant, cardiac ischemia in a stress test within 3 months before screening.
- Patients carrying implantable cardioverter defibrillators, cardiac resynchronisation therapy devices or left ventricular assist devices that had any significant clinical events requiring treatment or changes to background medical therapy such as ventricular tachycardias, ventricular fibrillation in the last 6 months before randomization while carrying the devices
- Primary and uncorrected valvular disease with foreseen requirement of valve repair within the next 6 months.
- Any stroke, TIA, any acute coronary syndrome within 6 months prior to randomization.
- Clinically relevant hepatic dysfunction at the screening visit indicated by at least one of the following:
- hepatic insufficiency (Child-Pugh B or C) as documented in medical history
- total bilirubin > 2 times the upper limit normal (ULN) and
- alanine amino transferase (ALT) > 3 times the ULN or
- glutamate dehydrogenase (GLDH) > 3 times the ULN or
- gamma glutamyl transpeptidase (GGT) > 5 times the ULN.
- Systolic blood pressure below 100 or above 160 mm Hg at the screening visit based on the average of 3 readings taken from the arm with the highest recordings.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BAY1142524 (5 mg)
12 patients with left-ventricular dysfunction after myocardial infarction, 9 patients allocated to verum treatment, 3 patients allocated to placebo treatment
|
5 mg BAY1142524 or placebo given as 5 mg IR tablet twice daily for 2 weeks
10 mg BAY1142524 or placebo given as 2 x 5 mg IR tablets twice daily as for 2 weeks
25 mg BAY1142524 or placebo given as 5 x 5 mg IR tablets twice daily for 2 weeks
50 mg BAY1142524 or placebo given 1 x 50 mg IR tablet once daily for 2 weeks
The patients will be treated orally with combinations of IR tablets containing placebo to achieve the indicated dosages.
|
Experimental: BAY1142524 (10 mg)
12 patients with left-ventricular dysfunction after myocardial infarction, 9 patients allocated to verum treatment, 3 patients allocated to placebo treatment
|
5 mg BAY1142524 or placebo given as 5 mg IR tablet twice daily for 2 weeks
10 mg BAY1142524 or placebo given as 2 x 5 mg IR tablets twice daily as for 2 weeks
25 mg BAY1142524 or placebo given as 5 x 5 mg IR tablets twice daily for 2 weeks
50 mg BAY1142524 or placebo given 1 x 50 mg IR tablet once daily for 2 weeks
The patients will be treated orally with combinations of IR tablets containing placebo to achieve the indicated dosages.
|
Experimental: BAY1142524 (25 mg)
12 patients with left-ventricular dysfunction after myocardial infarction, 9 patients allocated to verum treatment, 3 patients allocated to placebo treatment
|
5 mg BAY1142524 or placebo given as 5 mg IR tablet twice daily for 2 weeks
10 mg BAY1142524 or placebo given as 2 x 5 mg IR tablets twice daily as for 2 weeks
25 mg BAY1142524 or placebo given as 5 x 5 mg IR tablets twice daily for 2 weeks
50 mg BAY1142524 or placebo given 1 x 50 mg IR tablet once daily for 2 weeks
The patients will be treated orally with combinations of IR tablets containing placebo to achieve the indicated dosages.
|
Experimental: BAY1142524 (50 mg)
12 patients with left-ventricular dysfunction after myocardial infarction, 9 patients allocated to verum treatment, 3 patients allocated to placebo treatment
|
5 mg BAY1142524 or placebo given as 5 mg IR tablet twice daily for 2 weeks
10 mg BAY1142524 or placebo given as 2 x 5 mg IR tablets twice daily as for 2 weeks
25 mg BAY1142524 or placebo given as 5 x 5 mg IR tablets twice daily for 2 weeks
50 mg BAY1142524 or placebo given 1 x 50 mg IR tablet once daily for 2 weeks
The patients will be treated orally with combinations of IR tablets containing placebo to achieve the indicated dosages.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with adverse events
Time Frame: Up to 20 days
|
Up to 20 days
|
Number of participants with serious adverse events
Time Frame: Up to 20 days
|
Up to 20 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 17055
- 2014-005297-12 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
-
US Department of Veterans AffairsCompleted
Clinical Trials on BAY1142524
-
BayerCompletedDiabetic Kidney DiseaseSpain, Denmark, Bulgaria, Israel, Sweden, Finland, Italy
-
BayerCompletedMyocardial InfarctionSpain, Germany, Czechia, Israel, Italy